FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Clinical trial NCT06332092 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06332092
- Sponsor
- Fulgent Pharma LLC.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-10
- Primary completion
- 2025-12-31
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.